Targeted Therapy Treatment Innovations in AML - Episode 2

Role of Second Generation FLT3 Inhibitors in AML

Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.